Argos Therapeutics, Inc. (ARGS) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
On November 14, 2016, Argos Therapeutics, Inc. (the Company)
announced financial results for the three months and nine months
ended September 30, 2016. The full text of the press release
issued in connection with the announcement is furnished as
Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Form 8-K (including Exhibit 99.1) shall
not be deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934 (the Exchange Act) or otherwise subject to
the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933 or the Exchange Act, except as expressly set forth by
specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
The following exhibit relating to Item 2.02 shall be deemed to be
furnished, and not filed:
Press release dated November 14, 2016 entitled Argos
About Argos Therapeutics, Inc. (ARGS)